MARKET

SYBX

SYBX

Synlogic
NASDAQ
1.120
-0.030
-2.61%
Opening 11:10 12/05 EST
OPEN
1.150
PREV CLOSE
1.150
HIGH
1.150
LOW
1.120
VOLUME
2.75K
TURNOVER
--
52 WEEK HIGH
1.960
52 WEEK LOW
0.8980
MARKET CAP
13.10M
P/E (TTM)
-4.2667
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 23h ago
Weekly Report: what happened at SYBX last week (1124-1128)?
Weekly Report · 4d ago
Synlogic Challenges Nasdaq Delisting Notice
TipRanks · 11/26 22:48
Synlogic Says On Nov 21, Receives Letter From Nasdaq Listing Qualifications Department Stating It Believes Synlogic Is A 'Public Shell', Listing Not Warranted; Co Plans To Request Hearing
Benzinga · 11/26 22:30
SYNLOGIC INC - NASDAQ BELIEVES SYNLOGIC IS A 'PUBLIC SHELL', LISTING NOT WARRANTED - SEC FILING
Reuters · 11/26 22:28
Nasdaq Moves to Delist Synlogic Inc. Over Public Shell Concerns
Reuters · 11/26 22:26
Weekly Report: what happened at SYBX last week (1117-1121)?
Weekly Report · 11/24 09:03
Weekly Report: what happened at SYBX last week (1110-1114)?
Weekly Report · 11/17 09:03
More
About SYBX
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.

Webull offers Synlogic Inc stock information, including NASDAQ: SYBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYBX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYBX stock methods without spending real money on the virtual paper trading platform.